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Abstract: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by
inflammation of the synovial membrane, with thickening of the synovial layer, cellular hyperplasia,
and infiltration of immune cells. Mast cells (MCs) are cells of the innate immunity present in healthy
synovia and part of the cellular hyperplasia characterizing RA synovitis. Although their presence
in synovia has been well described, the exact functions and the correlation of MCs with disease
development and progression have been debated, particularly because of contradictory data obtained
in animal models and from patients with longstanding disease. Here, we present a revision of the
literature on MCs in RA, including the most recent observations obtained from patients with early
RA, indicating MCs as relevant markers of disease severity in early RA.
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1. Synovial Inflammation in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting the
joints [1]. The inflammation of the synovial membrane, i.e., synovitis, is characterized by thickening of
the synovial layer, with cellular hyperplasia and infiltration of various type of immune cells, including
cells of the innate and adaptive immunity, such as monocytes-macrophages, B and T cells, NK cells
and, last but not least, mast cells (MCs) [2]. Many of these immune cells and their mediators, known to
be relevant in the pathogenesis of RA [3], have become target of highly specific therapeutic options,
directed against mediators (e.g., TNF-alpha, IL-6), immune cells (e.g., CD20 B cells), and, more recently,
intracellular signaling pathways (e.g., Jak-Stat pathway inhibitors) [4]. These targeted treatments have
revolutionized the approach to RA, leading for the first time in decades to a shift in the paradigm from
considering RA as a chronic disease almost inexorably leading to disability to a disease that can be
controlled by the induction of remission [5]. Nonetheless, in many patients, the disease progresses
because of treatment failure, as up to 40% of patients do not respond to targeted treatment used as
first, second, or even third line strategies. To date, despite the progresses in our understanding of the
pathogenesis and the clinical features of RA [6], none of the proposed serum biomarkers have proven
useful in predicting treatment response, which remains one of the main unmet needs in the field [7].
The disappointment with respect to serum biomarkers includes the well-characterized anti-citrullinated
protein antibodies (ACPAs), which have become an invaluable diagnostic tool to identify a subset of
patients with worse prognostic features [8] but are of no use in the prediction of treatment response [9].
Therefore, in recent years, there has been a strong interest in the study of the synovial membrane as
a tool for patient stratification. The development of minimally invasive techniques, such as US-guided
synovial biopsies, has allowed for the analysis of the synovial membrane in patients with early RA and,
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very importantly, from small joints (e.g., metacarpophalangeal or wrists). This is in clear contrast with
previous studies using synovial tissues obtained from joint replacement surgery or by arthroscopy,
therefore biased by disease duration and treatment and by the analysis of large joints.
By studying the synovial tissue in large cohort of patients with early untreated RA, a marked
heterogeneity in the infiltration of immune cells has been described. More specifically, three distinct
histological patterns have been identified: (1) lympho-myeloid dominated by lymphoid lineage
infiltration (T cells, B cells, plasma cells) in addition to myeloid cells, (2) diffuse-myeloid with myeloid
lineage predominance but poor in B cells/plasma cells, and (3) pauci-immune characterized by scanty
immune cells and prevalent stromal cells [2]. Interestingly, the recent analysis of a large cohort (144) of
early RA patients naïve to treatment with steroids and immune-suppressors has shown an association
between the lympho-myeloid pathotype and disease severity, autoantibody positivity, and, most
importantly, radiographic progression [10].
Within the heterogeneous synovial infiltrate of lymphocytes and macrophages, MCs have also
emerged as immune cells relevant in the pathogenesis of RA and with potential predictive implications
in terms of disease progression and treatment response.
2. Emerging Role of Mast Cells in Synovial Inflammation
Tissue MCs and circulating basophils are the only cells that express the high affinity receptor
for IgE (FcεRI) and synthesize histamine in humans, although they differ morphologically and
immunologically [11,12]. These cells are mostly known as effector cells in allergic reactions in response
to antigens and superantigens [13], the mechanisms which account for their functions in allergic
diseases [14,15]. Compelling evidence indicates that MCs are involved in several pathophysiological
processes, including barrier homeostasis [16], angiogenesis and lymphangiogenesis [17,18], wound
healing [19], and tumorigenesis [20–22]. MCs have been known to be present in synovia for a long
time, but their relevance in the pathogenesis of RA has been somehow neglected, mainly because of
contradictory data coming from animal studies and the scarceness of studies in humans [23]. In the
early 1990s, our group published the first characterization of synovial human MCs, providing a detailed
description of the ultrastructural [24] and functional [25] features of synovial MCs. In parallel, other
groups described an increase of MC numbers in the synovia of RA patients, as summarized in Table 1
and described in detail in Section 3.5. However, the association of MCs with clinical features of disease
activity has been inconsistently reported, most likely because of the bias coming from the analysis long
standing disease and treatment with immune suppressors. Importantly, MCs have been more recently
described in other forms of inflammatory arthritis, such as spondyloarthritis [26] and osteoarthritis [27],
suggesting that their presence could be a common feature of synovial inflammation, although their
exact function as either effector cells or regulators of the immune response in these various settings
is yet to be clarified [28]. Several studies aimed at evaluating their role in animal models of arthritis
(reviewed in details in [23]), with the most recent publications confirming their relevance in the early
phases of the immune response leading to the development of arthritis [29,30]. In parallel, the analysis
of MCs in the synovia of a large cohort of patients with early RA unveiled their association with local
inflammation, disease severity, and autoantibody positivity, therefore confirming their relevance in
RA [31].
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Table 1. Summary of the studies analyzing synovial MCs in RA patients.
Year Title Disease Duration Procedure (Joint Site) Patients (n) Main Results
Crisp et al. 1984 [32] Articular mastocytosis inrheumatoid arthritis Long-standing
Synoviectomy (wrist
and knee) and joint
replacement (knee)
116
Higher MC numbers in RA vs.
healthy samples. Correlation with
synovitis but not with ESR. Caveat
treatment.
Godfrey et al. 1985 [33] Mast Cells in Rheumatoid Arthritisand Other Rheumatic Diseases Long-standing
Synoviectomy or joint
replacement 14
Higher MC numbers in RA.
Association with clinically active
disease.
Malone et al. 1987 [34] Mast cell numbers in rheumatoidsynovial tissues. Long-standing Knee arthroscopy 20
Correlation with synovial
inflammation. No attempt to look
for clinical correlations. Reduction
of MC numbers after IA steroids.
Tetlow & Woolley 1995 [35]
Distribution, activation and
tryptase/chymase phenotype of
mast cells in the rheumatoid
Long-standing Joint replacement(knee) 26
MC present in all samples, but
more abundant in 60% of patients.
Higher prevalence of MC_T. No
attempt to look for clinical
correlations.
Gotis-Graham & McNeil 1997 [36]
Mast cell responses in rheumatoid
synovium. Association of the
MCTC subset with matrix turnover
and clinical progression
Long-standing Joint replacement orarthroscopy (knee) 16
Increase of MCs in RA vs. OA or
healthy samples; MC_TC correlate
with disease activity.
Gotis-Graham et al. 1998 [37]
Synovial mast cell responses
during clinical improvement in
early rheumatoid arthritis
Early (mean disease
duration 8 months),
sDMARD-naïve
Arthroscopy (knee) 6
Relative increase of MC_T was
observed, in correlation with
synovial inflammatory score.
Ramírez et al. 2016 [38]
Immunopathologic
characterization of
ultrasound-defined synovitis in
rheumatoid arthritis patients in
clinical remission.
Long standing;
20 patients in remission;
22 with active disease
US-guided synovial
biopsies 42
MCs and B cells in patients in
clinical remission associated with
disease reactivation.
Rivellese et al. 2018 [31]
Mast cells in early rheumatoid
arthritis associate with disease
severity and support B cell
autoantibody production
Early (<12 months),
steroid and
sDMARD-naive
US-guided synovial
biopsies (60% small
joints, i.e., MCPs or
wrists)
99
Synovial MCs are associated with
(i) synovial inflammation, (ii)
lympho-myeloid infiltrate, (iii)
systemic inflammation, (iv)
autoantibodies, and (v) disease
activity.
1 sDMARDs: synthetic disease modifying antirheumatic drugs; MC_T: MC expressing tryptase; MC_TC: MC expressing tryptase and chymase; MCP: metacarpophalangeal, n: number
of patients.
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3. Synovial Mast Cells in Early RA
The unprecedented availability of synovial tissue from a large cohort of patients with early RA
naïve to treatment with steroids and immunosuppressors (http://www.peac-mrc.mds.qmul.ac.uk/ [10])
has represented an invaluable tool for the assessment of MCs in RA, allowing the analysis of synovial
MCs without the bias of disease duration or treatment [31]. In fact, apart from the few studies
mentioned above and summarized in Table 1, there has never been a systematic analysis of MCs in
the synovia of a large cohort of patients with RA. This study has demonstrated that MC presence in
synovia is associated with (i) synovial inflammation, (ii) lympho-myeloid aggregates, (iii) systemic
markers of inflammation (ESR, CRP), (iv) autoantibodies such as ACPAs and RF, and (v) disease activity.
Importantly, the concept of heterogeneity of synovial inflammation is relatively recent [2]. Therefore the
previous studies exploring MCs in RA, although describing variable levels of MC infiltration in synovia,
did not consider the possibility that MC infiltration could actually help stratifying patients, which is
the most important concept emerging from the recent studies. In the context of this heterogeneous
synovial inflammation, the study of synovial MC heterogeneity has also acquired particular relevance.
3.1. Synovial MC Heterogeneity
MCs complete their terminal differentiation in peripheral tissues, so their phenotype can be
influenced by the local microenvironment, leading to a marked phenotypic and functional heterogeneity,
which has been confirmed by recent transcriptomic analyses both in mice [39] and humans [40].
Classically, two types of MCs have been described in humans, based on the differential expression
of serine proteases: MC_TC, expressing both tryptase and chymase; MC_T expressing only tryptase.
The MC_TC subtype is predominantly found in skin, the gastrointestinal tract, and conjunctiva,
whereas the MC_T subtype is the predominant MC type in the lungs, nose, and sinuses [41].
In normal human synovia, over 90% of the MCs are MC_TC [24]. In long-standing RA, an
increase of both subtypes has been described, and MC_TC has been shown to be in correlation with
disease activity [36]. Another group, however, reported a higher prevalence of MC_T in patients with
long-standing RA [35], and in a small cohort of patients with early RA (n = 6) a relative increase of
the MC_T in correlation with synovial inflammatory score was observed [37]. These data have been
expanded by the recent observations coming from a large cohort of patients with early RA, confirming
the overall prevalence of MC_TC in RA, with a ratio of 3:1 over MC_T. However, interestingly, MC_T
were increased in the synovia of patients with lympho-myeloid infiltrates, in association with disease
severity. A summary of these evidences, including details on the heterogeneity of MCs in synovia
is offered in Table 1 and an example of MC_T and MC_TC from the synovia of an early RA patient
is presented in Figure 1. Overall, although the concept of MC heterogeneity will need to be further
explored while keeping into account their plasticity [42], the prevalence of MC_T in association with
the disease severity would be in line with the pro-inflammatory role of this subpopulation described in
asthma [43].
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Figure 1. Mast cell (MC) heterogeneity in synovia. (a) Immunofluorescence of synovia from an early 
rheumatoid arthritis (RA) patient showing MC with single positivity for tryptase (red)—MC_T; (b) 
MC double positive for tryptase (red) and chymase (green)—MC_TC. Nuclei in blue (DAPI). Line at 
20 µm. 
3.2. Synovial Mast Cells as Effector Cells in RA 
MCs have the capacity to rapidly perceive immunologic and metabolic insults and initiate 
different biochemical programs of homeostasis or inflammation. These cells can be activated by a 
plethora of immunologic and non-immunologic stimuli such as danger associated molecular patterns 
(DAMPs)-, viral and bacterial proteins [44,45], and endogenous ligands [46]. In the context of RA, 
specifically, laboratory evidence shows that MCs can produce pro-inflammatory (pro-arthritogenic) 
molecules [47], while on the other hand many stimuli can activate MCs in vitro, inducting the 
production of pro-inflammatory mediators. For example, ACPA immune complexes in synergy with 
toll-like receptor (TLR) ligands have been also shown to induce pro-inflammatory mediators, such as 
IL-8, from human MCs [48]. Similarly, the activation of synovial MCs has been linked to the 
production of several pro-inflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-1Ra [49]. 
Additionally, the synovial fluid possesses MC-chemotactic properties, as it contains stem cell factor 
(SCF), the main growth and chemotactic factor for MCs [50]. At the same time, the synovial fluid of 
RA patients also contains several mediators produced by MCs [51]. Finally, MC mediators can 
contribute to the aberrant survival and activation of human rheumatoid synovial fibroblasts [52]. 
Importantly, since MCs complete their differentiation in tissues, many of the stimuli known to be 
present in synovia can contribute to their differentiation. While the exact pathways leading to human 
MC differentiation from circulating precursors are still debated [53], the two main stimuli needed for 
human MC differentiation in vitro (SCF and IL-6) are well-known to be present in synovia. 
Interestingly, higher SCF levels have been described in RA [50], and IL-6 a central cytokine in RA 
pathogenesis is targeted by biologicaltreatments [3]. The key effector functions of MCs in synovial 
inflammation are shown in Figure 2. Overall, these data support a pathogenic role as effector cells in 
RA. 
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3.2. Synovial Mast Cells as Effector Cells in RA
MCs have the capacity to rapidly perceive immunologic and metabolic insults and initiate
different biochemical programs of homeostasis or inflammation. These cells can be activated by a
plethora of immunologic and non-immun logic stimuli such as danger associated molecular patterns
(DAMPs)-, viral and bacterial proteins [44,45], and endogenous li ands [46]. In the context of RA,
specifically, laboratory evidence shows that MCs can pr duce pro-inflammatory (pro-arthritogenic)
molecules [47], while on the other hand many stimuli can activate MCs in vitro, inducting the
pr duction of pro-inflammatory mediators. For example, ACPA immune complexes in synergy with
toll-like receptor (TLR) ligands have been als shown to induce pro-inflam atory mediators, suc
as IL-8, from human MCs [48]. Similarly, the activatio of syn vial MCs has been linked to the
production of several pro-inflam atory cytokines, such as TNF-alpha, IL-1beta, and IL-1Ra [49].
Additionally, the synovial fluid possesses MC-chemotactic properties, s it contains stem cell factor
(SCF), the main growth nd chemotactic factor for MCs [50]. At the s me time, the synovial fluid
of RA patients als cont ins several mediators produced by MCs [51]. Finally, MC mediators can
contribute to the aberra t survival an ctivation of human rheumatoid synovial fibroblasts [52].
Importantly, since MCs complete their differentiati n in tissues, many of the stimuli known to be
present i s novia can contribute to their differentiation. While the exact pathways leading to human
MC differentiation from circulating pr cursors are still debated [53], the two main stimuli needed for
human MC differe tiation in vitro (SCF and IL-6) are well-known to be present in synovia. Interestingly,
igher SCF levels have been described in RA [50], and IL-6 a central cytokine in RA pathogenesis is
targeted by biologicaltreatments [3]. Th key ffector functions of MCs in synovial inflammatio are
shown i Figure 2. Ov rall, these dat support a pathogenic role as effector cells in RA.
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Figure 2. Synovial mast cell (MC): cellular interactions and effector functions. This illustration 
summarizes the main functions of synovial MCs with relevance in the pathogenesis of RA. Examples 
of factors capable of triggering MC activation are shown, such as immune complexes [54], cytokines 
and chemokines [50], and endogenous toll-like receptor (TLR) ligands [48]. The cellular interactions 
with immune cells are shown on the left: antigen presentation to T cells [55,56]; B cell co-stimulation 
via CD40–CD40L and soluble mediators (e.g., IL-6), inducing the production of auto-antibodies [31]; 
modulation of monocyte-macrophages activation [57]. Finally, on the right, the effector functions of 
MCs are summarized, with an emphasis on the induction of bone erosions, which can be mediated 
directly by MC-derived proteases [58] or indirectly via the activation of osteoclasts [59,60]. Green 
arrows indicate the effects of proinflammatory citokines; the “T” bar indicates the effects of 
antinflammatory citokines. 
3.3. Synovial Mast Cells and the Activation of Lymphocyte 
The observation of synovial MCs in association with B and T cell infiltrates in synovia led to the 
hypothesis that MCs can influence the activation of lymphocytes. Indeed, both mouse and human 
MCs express MHC class II and can function as antigen presenting cells, inducing antigen-specific T 
cell activation [55,56,61]. More recently, MCs have also been shown to induce Th17 differentiation 
via inflammasome-independent IL1β [62]. Overall, the ability of MCs to influence T cell activation is 
in line with recent data in animal models, showing that in MC-depleted animals the reduced severity 
of collagen-induced arthritis was also accompanied by a dramatic loss of T cell expansion and 
reduced T cell cytokine responses [30]. However, while T cells are essential for the break of tolerance 
and the initiation and perpetuation of the aberrant immune response, B cells also have a well-
established role in RA [63,64]. In fact, the presence of B cells in synovia has been linked to local 
autoantibody production [65,66], osteoclastogenesis/osteoclast activation [67,68], and immune-
complex-mediated inflammatory responses [69,70]. Therefore, the possible cross-talk between MCs 
and B cells is also of relevance in RA. Interestingly, mouse MCs have been described to activate B 
cells [71,72]. More recently, human MCs were found to induce the activation and differentiation of B 
cells, including the production of ACPAs [31]. In line with previous data in animal models [71], these 
effects were found to be dependent on cell–cell contact, with a specific role for CD40L expressed by 
MCs. We were also able to observe for the first time a direct interaction between human MCs and B 
cells, as previously shown for mouse MCs and DCs [73] and, very recently, T cells [74]. Overall, these 
data suggest that MCs, in addition to their established role as effector cells, can influence the adaptive 
immune response by inducing T and B cell activation, which further confirms their relevance in the 
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3.3. Synovial Mast Cells and the Activation of Lymphocyte
The observation of synovial MCs i associati n with B and T cell infiltrates in synovia led to the
hypothesis that MCs can influence the activation of lymphocytes. Indeed, both mouse and human
MCs express MHC class II and can function as antigen presenting cells, inducing antigen-specific T
cell activation [55,56,61]. More recently, MCs have also been shown to induce Th17 differentiation via
inflammasome-independent IL1β [62]. Overall, the ability of MCs to influence T cell activation is in
line with recent data in animal models, showing that in MC-depleted animals the reduced severity of
collagen-induced arthritis was also accompanied by a dramatic loss of T cell expansion and reduced
T cell cytokine responses [30]. However, while T cells are essential for the break of tolerance and
the initiation and perpetuation of the aberrant immune response, B cells also have a well-established
role in RA [63,64]. In fact, the presence of B cells in synovia has been linked to local autoantibody
production [65,66], osteoclastogenesis/osteoclast activation [67,68], and immune-complex-mediated
inflammatory responses [69,70]. Therefore, the possible cross-talk between MCs and B cells is also
of relevance in RA. Interestingly, mouse MCs have been described to activate B cells [71,72]. More
recently, human MCs were found to induce the activation and differentiation of B cells, including the
production of ACPAs [31]. In line with previous data in animal models [71], these effects were found
to be dependent on cell–cell contact, with a specific role for CD40L expressed by MCs. We were also
able to observe for the first time a direct interaction between human MCs and B cells, as previously
shown for mouse MCs and DCs [73] and, very recently, T cells [74]. Overall, these data suggest
that MCs, in addition to their established role as effector cells, can influence the adaptive immune
response by inducing T and B cell activation, which further confirms their relevance in the induction
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and progression of autoimmune diseases such as RA. An overview of the key interactions of MCs with
immune cells in synovia is presented in Figure 2.
3.4. Mast Cells as Immunomodulatory Cells in RA
Convincing evidence, as presented in the previous sections, suggests that MCs can have a
prominent role as effector cells in RA and other autoimmune conditions. Nonetheless, MCs are also
highly tunable cells, capable of influencing the immune responses towards pro- or anti-inflammatory
responses, depending on the type of environment and triggers they are exposed to [75]. For example,
in the context of arthritis, when triggered with TLR-ligands and immune complexes, they have been
shown to produce pro-inflammatory mediators [48]. However, in response to IL-33 and immune
complexes, MCs can also produce immunomodulatory mediators, which in turn dampen the activation
of monocytes [57]. These immunomodulatory effects are mediated by preformed mediators, such as
histamine, but also newly produced mediators, such as IL-10. Interestingly, histamine is best known
as the main pro-inflammatory mediator released by MCs and basophils upon IgE-triggering and is
able to mediate the typical symptoms and signs of allergic reactions. However, an increasing amount
of evidence suggests that histamine can also induce immunomodulatory and anti-inflammatory
effects [76,77]. The potential immunomodulatory functions of MCs in RA are supported by the
observation that the serum levels of tryptase and the synovial tryptase mRNA show an inverse
correlation with inflammatory markers [78,79]. Overall, there are convincing observations suggesting
that MCs can play multifaceted roles in RA. Given the complexity and heterogeneity of RA, however,
it is possible to hypothesize that MCs could have different roles in various patients and in the different
stages of disease evolution. The only way to confirm this hypothesis is to assess their function
systematically, by analyzing their presence in a large cohort of patients at different disease stages and,
importantly, in correlation with disease activity. Over the last few years, a number of studies have
attempted to tackle the issue of MC presence in the synovia of RA patients, yielding contrasting results
that we will review in the next section.
3.5. Synovial Mast Cells as Markers of Disease Severity in Early and Established RA
As summarized in Table 1, a number of studies have explored the presence of MCs in the synovia
of patients with RA. The first observations came from two parallel studies by Crisp et al. and Godfrey
et al. The first group analyzed the synovial membrane obtained by either synovectomy or joint
replacement from 116 patients with RA. They observed significantly higher MC numbers in RA vs.
healthy controls and a correlation of high MC numbers with clinically active synovitis (i.e., swollen
joints) but not with ESR [32]. In parallel, Godfrey et al. analyzed a smaller cohort of 14 patients with
RA undergoing synoviectomy or joint replacement, again demonstrating higher MC numbers in RA
vs. healthy controls [33]. After a few years, another group assessed MCs in the synovia obtained by
knee arthroscopy from 20 patients with RA, demonstrating a correlation with synovial inflammation
and, interestingly, a reduction of MC numbers after intra-articular steroids in a subset of patients [34].
Accordingly, the study by Tetlow et al. showed increased numbers of MCs in the synovial membrane
of RA patients (n = 26). For the first time, this group also looked at MC heterogeneity, demonstrating
a higher prevalence of MC_T (see Section 3.1 for a detailed discussion on MC heterogeneity) [35].
Overall, in these studies, no attempt to correlate MCs with clinical disease activity was made, and
an important limitation is the inclusion of patients with long-standing disease, therefore biased by
treatment, which, as directly demonstrated by Tetlow et al., can significantly affect MC numbers
in synovia. Gotis-Graham et al. observed an association of synovial MCs with disease activity in
16 patients with established RA. More specifically, the authors observed that MC_TC, a subset of
MCs expressing both tryptase and chymase, is expanded in RA and correlates with parameters of
disease activity and progression [36]. In a subsequent study, the same authors analyzed the synovial
tissue obtained by arthroscopy from 6 patients with early RA (mean disease duration 8 months),
demonstrating that early in the course of disease the expansion of MCs is predominantly of the
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MC_T subset, expressing only tryptase, thus suggesting that different MC subsets might have distinct
functions in early vs. late RA [37]. Overall, the results of these studies support the relevance of MCs in
the pathogenesis of RA, but the limitations due to disease duration, treatment, and the small number
of patients made the interpretation of these results very difficult. It is also important that the above
studies did not take into account the clinical and histological heterogeneity of RA, which has emerged
in recent years as an important aspect of RA etiopathogenesis [2]. It would be intriguing to speculate
that MCs have distinct functions in different patient subsets, and, possibly, at different disease stages.
Unfortunately, while there have been many attempts to understand the contribution MCs to arthritis
using animal models or in vitro experiments [23], to our knowledge for almost 20 years no other study
has attempted to analyze MCs in the synovia of RA patients. The development of ultrasound-guided
biopsies has helped to overcome such limitations, allowing the study of synovial inflammation early in
the course of the disease [2]. Ramirez et al., by analyzing synovial biopsies from patients with RA in
remission, demonstrated that the numbers of synovial MCs and B cells were significantly higher in
patients who did not maintain remission after one year [38]. More recently, our group has analyzed
the presence of MCs in the synovia of a large cohort (n = 99) of patients with early, untreated RA,
demonstrating a correlation of MC numbers with local synovitis but also systemic inflammation and
disease activity. Importantly, the analysis of synovial MCs allowed for the stratification of patients into
groups (low, medium, and high synovial MCs) with different levels of disease activity at baseline [31].
Overall, these data suggest that the analysis of synovial MCs could be used as a biomarker to predict
disease severity, progression, and, hopefully, treatment response, although confirmation in larger
cohorts and the analysis of longitudinal data pre-post treatment will be needed to further clarify the
contribution of MCs to RA and their ability to predict treatment progression and response.
4. Concluding Remarks and Future Work
MCs have emerged in recent years as relevant cells in the pathogenesis of RA. Here, we offer a
comprehensive review of data on MCs in early RA showing (i) an increase in the numbers of MCs
in the synovial membrane of RA patients, (ii) the contribution of MCs to the local inflammatory
process via the production of several pro-inflammatory mediators, (iii) the ability of MCs to act
as tunable cells by inducing anti-inflammatory responses, and (iv) the correlation of synovial MCs
with local and systemic inflammation and disease inflammation. MC key interactions with other
immune cells in synovia and their effector functions are summarized in Figure 2. Overall, the evidence
presented in this review support a role for MCs in the pathogenesis of RA. Moreover, the data from
patients, summarized in Table 1, suggests that the analysis of synovial MCs could help to stratify
RA patients. However, an outstanding question remains, whether MCs could be used as markers of
disease progression and treatment response. Interestingly, some of the most recent targeted therapies
in RA, small molecules inhibiting Janus kinases signaling, have the potential to inhibit the activation
of MCs [4], although it is difficult to dissect the specific effects of such treatments on MCs vs. other
immune cells. As for their potential relevance as markers of disease progression and treatment response,
future analysis of synovial MCs in well-powered biopsy-driven clinical trials exploring the use of
synovial histology for patient stratification to different therapies (http://www.r4ra-nihr.whri.qmul.ac.uk
and http://www.matura-mrc.whri.qmul.ac.ukwill) hocns soon.
Author Contributions: All authors have contributed to the preparation of this manuscript and have critically
revised and accepted the final version for publication.
Funding: F. Rivellese is funded by an NIHR Transitional Research Fellowship. The cohorts mentioned in this
review were funded by the following grants: Pathobiology of Early Arthritis Cohort (PEAC), MRC grant 36661;
R4RA (A Randomised, open labeled trial investigating the mechanisms for Response-Resistance to RTX versus
TOC in anti-TNFα-ir RA patients”-EudraCT number 2012-002535-28), NIHR-EME Grant Ref 11/100/76; and STRAP
(Stratification of Therapy for RA by Pathobiology”-EudraCT number 2014-003529-16), MRC Strategic Grant
MR/K015346/1. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR,
or the Department of Health and Social Care or any other funding body.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2019, 20, 2040 9 of 13
Abbreviations
ACPAs anti-citrullinated protein antibodies
CRP C reactive protein
DAPI 4′,6-diamidino-2-phenylindole
ESR erytrocyte sedimentation rate
FcεRI Fc epsilon receptor I
MC mast cell
MC_TC mast cell expressing tryptase and chymase
MC_T mast cell expressing tryptase
RANK receptor activator of nuclear factor kappa-β
RANKL receptor activator of nuclear factor kappa-β ligand
SCF stem cell factor
sDMARDs synthetic disease modifying anti-rheumatic drugs
TLR toll-like receptors
TNFα tumor necrosis factor alpha
VEGF vascular endothelial growth factor
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